Armistice Capital, LLC Fibrogen Inc Transaction History

Armistice Capital, LLC

$6.56 Billion
Q1 2025

A detailed history of Armistice Capital, LLC transactions in Fibrogen Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 8,500,000 shares of FGEN stock, worth $2.55 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

8,500,000

Previous 6,800,000 25.0%

Holding current value

$2.55 Million

Previous $3.6 Million 26.89%

% of portfolio

0.04%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.31 - $0.77 $527,000 - $1.31 Million	1,700,000 Added 25.0%	8,500,000 $2.64 Million
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $704,880 - $2.69 Million	-2,136,000 Reduced 23.9%	6,800,000 $2.72 Million
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $890,000 - $2.36 Million	1,000,000 Added 12.6%	8,936,000 $7.95 Million
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $1.33 Million - $4.99 Million	-1,828,000 Reduced 18.72%	7,936,000 $18.6 Million
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.91 $711,360 - $1.7 Million	1,872,000 Added 23.72%	9,764,000 $8.69 Million
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $2.79 Million - $10 Million	3,536,000 Added 81.18%	7,892,000 $6.79 Million
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $5.09 Million - $42.1 Million	2,044,000 Added 88.41%	4,356,000 $11.8 Million
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $24.8 Million - $39.1 Million	-1,552,000 Reduced 40.17%	2,312,000 $43.1 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $7.86 Million - $10.5 Million	-592,000 Reduced 13.29%	3,864,000 $61.9 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $4.15 Million - $5.31 Million	364,000 Added 8.9%	4,456,000 $58 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $32.5 Million - $53 Million	4,092,000 New	4,092,000 $43.2 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

34.6M

Call Options Held

461K

Put Options Held

102K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $28.1M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Fibrogen Inc Transaction History